![PDF] Aberrant RNA Splicing in Cancer and Drug Resistance | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1e455e23cd18162830fba4eeb550aac99b08417d/12-Figure5-1.png "PDF] Aberrant RNA Splicing in Cancer and Drug Resistance | Semantic Scholar")
PDF] Aberrant RNA Splicing in Cancer and Drug Resistance | Semantic Scholar
David Steensma, MD on Twitter: "#H3B-8800 #SF3B1 inhibitor #MDS #AML Phase 1; we treated 81 patients and defined MTD as 30 mg 5d on 9 day off schedule and saw deep modulation
Evolving therapies for lower-risk myelodysplastic syndromes | SpringerLink
Cancers | Free Full-Text | Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features | HTML
RVT-2001 / Eisai, Roivant
Splicing modulators: on the way from nature to clinic | The Journal of Antibiotics
Splicing modulator H3B-8800 in myeloid malignancies: phase 1 results | VJHemOnc
H3B-8800 modulates splicing and selectively kills SF3B1-mutant leukemia... | Download Scientific Diagram
Aberrant RNA splicing and therapeutic opportunities in cancers - Yamauchi - 2022 - Cancer Science - Wiley Online Library
Eisai out-licenses cancer candidate H3B-8800 to Roivant
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers | Request PDF
Reprogramming RNA processing: an emerging therapeutic landscape: Trends in Pharmacological Sciences
H3B-8800 inhibits splicing of short, GC-rich introns and affects... | Download Scientific Diagram
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B -8800 in myeloid neoplasms | Leukemia
Production of novel pladienolide analogues through native expression of a pathway-specific activator - Chemical Science (RSC Publishing) DOI:10.1039/D0SC01928C
Selected novel agents in clinical trials for lower-risk MDS Several... | Download Scientific Diagram
H3B-8800 | Chemistry Information PDF | PharmaCompass.com
Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience. - Abstract - Europe PMC
Therapeutic approaches to treat human spliceosomal diseases. - Abstract - Europe PMC
Science | H3 Biomedicine
Screening Approaches for Targeting Ribonucleoprotein Complexes: A New Dimension for Drug Discovery - ScienceDirect
H3 Biomedicine Publishes Comprehensive Genomic Landscape Analysis in Cell Reports Revealing Breadth, Frequency and Potential Disease-Driving Significance of Somatic Mutations in RNA Splicing Factor Genes in Multiple Types of Cancer | Business
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B -8800 in myeloid neoplasms | Leukemia
Small Molecule of the Year – 2021 - Drug Hunter
H3B-8800 pharmacokinetics Plasma concentration in ng/mL of H3B-8800 on... | Download Scientific Diagram
Spliceostatin A interaction with SF3B limits U1 snRNP availability and causes premature cleavage and polyadenylation - ScienceDirect
